hrcak mascot   Srce   HID

Pregledni rad

Recent advances in clinical anti-cancer immunotherapy

ANTONIO JURETIĆ   ORCID icon orcid.org/0000-0002-6379-9708 ; School of Medicine and Clinical Hospital Center Zagreb, Department of Oncology, Zagreb, Croatia

Puni tekst: engleski, pdf (803 KB) str. 365-370 preuzimanja: 293* citiraj
APA 6th Edition
JURETIĆ, A. (2014). Recent advances in clinical anti-cancer immunotherapy. Periodicum biologorum, 116 (4), 365-370. Preuzeto s https://hrcak.srce.hr/138018
MLA 8th Edition
JURETIĆ, ANTONIO. "Recent advances in clinical anti-cancer immunotherapy." Periodicum biologorum, vol. 116, br. 4, 2014, str. 365-370. https://hrcak.srce.hr/138018. Citirano 13.08.2020.
Chicago 17th Edition
JURETIĆ, ANTONIO. "Recent advances in clinical anti-cancer immunotherapy." Periodicum biologorum 116, br. 4 (2014): 365-370. https://hrcak.srce.hr/138018
Harvard
JURETIĆ, A. (2014). 'Recent advances in clinical anti-cancer immunotherapy', Periodicum biologorum, 116(4), str. 365-370. Preuzeto s: https://hrcak.srce.hr/138018 (Datum pristupa: 13.08.2020.)
Vancouver
JURETIĆ A. Recent advances in clinical anti-cancer immunotherapy. Periodicum biologorum [Internet]. 2014 [pristupljeno 13.08.2020.];116(4):365-370. Dostupno na: https://hrcak.srce.hr/138018
IEEE
A. JURETIĆ, "Recent advances in clinical anti-cancer immunotherapy", Periodicum biologorum, vol.116, br. 4, str. 365-370, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/138018. [Citirano: 13.08.2020.]

Sažetak
Recent successful results with the relatively novel immunotherapeutic
anti-cancer strategies such as adoptive T cell transfer (ACT), engineered T
cells with chimeric antigen receptors (CARs), therapeutic Sipuleucil-T vaccine and checkpoint blockade inhibitors, do indicate that patient’s immune system can be effectively used against autologous tumor cells. Interactions between the immune system and the malignancy are complex but the results obtained using the above mentioned therapeutic approaches indicate acceptable clinical utility, efficacy and safety against several types of cancer. Much work still lies ahead but the success achieved with these modern immunotherapies is undeniable. This paper aims to present a short basic overview of these recent advances in cancer immunotherapy, but one should keep in mind that this field is in a dynamic stage given its success and that many immunotherapeutic agents, not all of them mentioned, are undergoing active
clinical testing.

Hrčak ID: 138018

URI
https://hrcak.srce.hr/138018

Posjeta: 448 *